

North Ottawa Community Health System
 Cumulative Antimicrobial Susceptibility Summary Jan. 1, 2021 - Dec. 31, 2021
 BioMerieux Vitek® 2 MIC Methodology

NON-URINE SOURCE

Organism	%Susceptible																														
	# Isolates	Ampicillin	Amp/Sulbactam	Cefazolin	Cefepime	Cefotaxime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Clindamycin	Daptomycin	Doxycycline	Ertapenem	Erythromycin	Gentamicin	Gentamicin(high level)	Imipenem	Levofloxacin	Linezolid	Moxifloxacin	Oxacillin	Penicillin	Penicillin (oral)	Pip/Tazobactam	Rifampin	Streptomycin (high level)	Tetracycline	Tigecycline	Tobramycin	T/S	Vancomycin
<i>Coagulase Negative Staph</i>	26 ¹	*	*	*	*	*	*	*	81	64	100	86	*	46	92	*	*	81	100	96	54	*	*	*	100	*	77	100	*	77	100
<i>Enterococcus faecalis</i>	47	100	*	*	*	*	*	*	89	*	100	14	*	15	*	91	*	89	96	*	*	*	*	*	94	30	100	*	*	100	
<i>Escherichia coli</i>	50	56	62	94	94	*	94	94	94	*	*	*	100	*	80	*	100	94	*	*	*	*	*	98	*	*	*	*	84	78	*
<i>ESBL-producing E Coli</i>	3 ¹	0	33	0	0	*	0	0	33	*	*	*	100	*	33	*	100	33	*	*	*	*	*	100	*	*	*	*	33	67	*
<i>Pseudomonas aeruginosa</i>	30	*	*	0	93	*	93	*	100	*	*	*	*	*	100	*	100	87	*	*	*	*	*	93	*	*	*	*	100	*	*
<i>Staphylococcus aureus</i>	155	*	*	*	*	*	*	*	77	83	100	100	*	52	99	*	*	82	100	96	72	*	*	*	100	*	94	100	*	98	100
<i>Methicillin Resistant Staph aureus</i>	44	*	*	*	*	*	*	*	55	80	100	100	*	18	100	*	*	64	100	93	0	*	*	*	100	*	93	100	*	100	100
<i>Methicillin Susceptible Staph aureus</i>	111	*	*	*	*	*	*	*	86	84	100	100	*	66	98	*	*	89	100	97	100	*	*	*	100	*	94	100	*	97	100
<i>Streptococcus agalactiae</i>	13 ¹	100	*	*	*	100	*	100	*	38	*	*	*	23	*	*	*	92	100	100	*	100	*	*	*	23	100	*	*	100	
<i>Streptococcus pneumoniae</i> ²	11 ²	*	*	*	*	#	*	#	*	100	*	*	*	100	*	*	*	100	100	100	*	#	100	*	*	*	100	100	*	100	100
<i>Str. Pneumo-meningitis</i>	11 ²	*	*	*	*	100	*	100	*	*	*	*	*	*	*	*	*	*	*	*	*	100	*	*	*	*	*	*	*	*	*
<i>Str. Pneumo-nonmeningitis</i>	11 ²	*	*	*	*	100	*	100	*	*	*	*	*	*	*	*	*	*	*	*	*	100	*	*	*	*	*	*	*	*	*

URINE SOURCE

Organism	%Susceptible																												
	# Isolates	Ampicillin	Amp/Sulbactam	Cefazolin	Cefepime	Cefotaxime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Ertapenem	Daptomycin	Doxycycline	Gentamicin	Gentamicin(high level)	Imipenem	Levofloxacin	Linezolid	Moxifloxacin	Nitrofurantoin	Oxacillin	Penicillin	Pip/Tazobactam	Rifampin	Streptomycin (high level)	Tetracycline	Tigecycline	Tobramycin	T/S	Vancomycin
<i>Coagulase negative staph</i>	77	*	*	*	*	*	*	*	75	*	100	94	96	*	*	75	100	90	100	55	*	*	100	*	87	100	*	78	100
<i>Enterococcus faecalis</i>	143	100	*	*	*	*	*	*	81	*	100	37	*	82	*	84	97	*	100	*	*	*	89	34	100	*	*	*	100
<i>Escherichia coli</i>	973	63	70	93	97	*	95	96	90	100	*	*	94	*	100	89	*	*	98	*	*	98	*	*	*	*	94	83	*
<i>ESBL-producing E Coli</i>	40	0	44	0	44	*	5	13	29	98	*	*	68	*	98	28	*	*	88	*	*	95	*	*	*	*	59	65	*
<i>Klebsiella oxytoca</i>	35	0	71	86	100	*	100	100	97	100	*	*	97	*	100	100	*	*	89	*	*	97	*	*	*	*	97	94	*
<i>Klebsiella pneumoniae</i>	161	0	93	97	99	*	97	98	98	100	*	*	98	*	100	98	*	*	24	*	*	99	*	*	*	*	98	94	*
<i>Proteus mirabilis</i>	89	85	93	97	100	*	100	100	58	100	*	*	93	*	97	60	*	*	0	*	*	100	*	*	*	*	94	73	*
<i>Pseudomonas aeruginosa</i>	56	*	*	0	95	*	95	*	89	*	*	*	100	*	93	84	*	*	*	*	*	96	*	*	*	*	100	*	*
<i>Staphylococcus aureus</i>	34	*	*	*	*	*	*	*	47	*	*	*	100	*	47	100	76	100	59	*	*	100	*	88	100	*	97	100	
<i>Methicillin Resistant Staph aureus</i>	14 ¹	*	*	*	*	*	*	*	0	*	100	100	100	*	*	0	100	50	100	0	*	*	100	*	100	100	*	93	100
<i>Methicillin Susceptible Staph aureus</i>	20 ¹	*	*	*	*	*	*	*	80	*	100	100	100	*	*	80	100	95	100	100	*	*	100	*	80	100	*	100	100
<i>Streptococcus agalactiae</i>	10 ¹	100	*	*	*	100	*	100	*	*	*	*	*	*	100	100	100	*	*	100	*	*	*	30	100	*	*	100	

*Drug not tested or drug not indicated

Breakpoints differ based on diagnosis

¹less than desirable # of isolates for statistical validity, ≥30 is considered clinically significant

²represents only those isolates which screen Intermediate or Resistant to oxacillin